Literature DB >> 1639392

A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.

Y Ma1, B I Wilson, S Bijvoet, H E Henderson, E Cramb, G Roederer, M R Ven Murthy, P Julien, H D Bakker, J J Kastelein.   

Abstract

We have previously reported two common lipoprotein lipase (LPL) gene mutations underlying LPL deficiency in the majority of 37 French Canadians (Monsalve et al., 1990. J. Clin. Invest. 86: 728-734; Ma et al., 1991. N. Engl. J. Med. 324: 1761-1766). By examining the 10 coding exons of the LPL gene in another French Canadian patient, we have identified a third missense mutation that is found in two of the three remaining patients for whom mutations are undefined. This is a G to A transition in exon 6 that results in a substitution of asparagine for aspartic acid at residue 250. Using in vitro site-directed mutagenesis, we have confirmed that this mutation causes a catalytically defective LPL protein. In addition, the Asp250----Asn mutation was also found on the same haplotype in an LPL-deficient patient of Dutch ancestry, suggesting a common origin. This mutation alters a TaqI restriction site in exon 6 and will allow for rapid screening in patients with LPL deficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639392     DOI: 10.1016/0888-7543(92)90136-g

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  10 in total

1.  Assessment of French patients with LPL deficiency for French Canadian mutations.

Authors:  L Foubert; J L De Gennes; J P Lagarde; E Ehrenborg; A Raisonnier; J P Girardet; M R Hayden; P Benlian
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

Review 2.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

3.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.

Authors:  R P Surendran; M E Visser; S Heemelaar; J Wang; J Peter; J C Defesche; J A Kuivenhoven; M Hosseini; M Péterfy; J J P Kastelein; C T Johansen; R A Hegele; E S G Stroes; G M Dallinga-Thie
Journal:  J Intern Med       Date:  2012-02-13       Impact factor: 8.989

4.  Palmar Striated Xanthomas in Clinical Practice.

Authors:  Nathalie Roy; Daniel Gaudet; Diane Brisson
Journal:  J Endocr Soc       Date:  2022-07-02

5.  Support for founder effect for two lipoprotein lipase (LPL) gene mutations in French Canadians by analysis of GT microsatellites flanking the LPL gene.

Authors:  S Wood; M Schertzer; M Hayden; Y Ma
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

Review 6.  Molecular genetics of human lipoprotein lipase deficiency.

Authors:  M R Hayden; Y Ma
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

7.  Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes.

Authors:  P Perron; D Brisson; M Santuré; P Blackburn; J Bergeron; M C Vohl; J P Després; D Gaudet
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

Review 8.  Common mutations of the lipoprotein lipase gene and their clinical significance.

Authors:  S Gehrisch
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.967

9.  Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration.

Authors:  Nathalie Roy; Daniel Gaudet; Gérald Tremblay; Diane Brisson
Journal:  Lipids Health Dis       Date:  2020-05-19       Impact factor: 3.876

Review 10.  Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia.

Authors:  György Paragh; Ákos Németh; Mariann Harangi; Maciej Banach; Péter Fülöp
Journal:  Lipids Health Dis       Date:  2022-02-10       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.